Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Randomized Study to Evaluate Multiple Dosing Regimens of Subcutaneous PL8177 Administration in Subjects With Non Infectious Uveitis (NIU)

Next Previous
Trial Profile

A Phase 2, Open-Label Randomized Study to Evaluate Multiple Dosing Regimens of Subcutaneous PL8177 Administration in Subjects With Non Infectious Uveitis (NIU)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PL 8177 (Primary)
  • Indications Anterior uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis; Uveitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Palatin Technologies

Most Recent Events

  • 12 May 2020 According to a Palatin Technologies media release, the company currently anticipates filing an IND and commencing clinical trials with PL8177 for non-infectious uveitis, in the second half of calendar year 2021.
  • 24 Sep 2019 Status changed from planning to not yet recruiting.
  • 06 Aug 2019 According to a Palatin Technologies media release, the study is anticipated to commence in the first quarter of calendar year 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top